OKYO Pharma (NASDAQ:OKYO) Earns “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of OKYO Pharma (NASDAQ:OKYO) in a report published on Thursday morning, Benzinga reports. HC Wainwright currently has a $7.00 price objective on the stock. HC Wainwright also issued estimates for OKYO Pharma’s Q2 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.09) EPS and FY2025 earnings at ($0.40) EPS.

OKYO Pharma Price Performance

Shares of OKYO Pharma stock opened at $1.26 on Thursday. The business has a 50-day moving average price of $1.05 and a 200 day moving average price of $1.24. OKYO Pharma has a fifty-two week low of $0.81 and a fifty-two week high of $2.12.

OKYO Pharma Company Profile

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.